Natural Products for Depression: Preclinical Insights into Microbiota–Gut–Brain Axis Modulation and Pharmacological Potential
Xikai Qiao, Donghe Han, Yuying Bai, Rongxin Wang, Xiaocong Xue, Z. X. Wang, Mei Hua Jin, Ran Tao
Dalian Medical University Open University of China
阅读操作
确认中在文库中上传 PDF 后可生成中文音频讲解。
摘要与影响
The microbiota-gut-brain axis (MGBA) is progressively associated with the pathophysiology of depression. This analysis consolidates existing preclinical findings on MGBA mechanisms associated with depression and assesses natural-product therapies through three key metabolite-related pathways: bile acid-responsive signaling via the farnesoid X receptor, G protein-coupled bile acid receptor 1, vitamin D receptor, and pregnane X receptor; metabolites from the kynurenine pathway and their connection to N-methyl-D-aspartate receptor signaling; and microbial indole-aryl hydrocarbon receptor signaling. Bile acid-responsive receptors and signaling pathways are examined as a system connecting microbiota-altered bile acid profiles to receptor-specific impacts on bile acid equilibrium, epithelial barrier integrity, immune modulation, metabolic signaling, and subsequent neuroplasticity-related reactions. These metabolite-associated domains converge with extensive MGBA mechanisms, encompassing short-chain fatty acid signaling, vagal interactions, serotonergic modulation, gamma-aminobutyric acid signaling, hypothalamic-pituitary-adrenal axis function, and barrier-immune pathways. In this analytical framework, natural products from marine and terrestrial sources are evaluated across several mechanistic domains and evidence levels, with direct host-target interactions, microbiota-related alterations, and experimentally validated microbiota-dependent pathways examined independently. This method facilitates a more nuanced evaluation of diverse preclinical results by elucidating the extent of mechanistic backing and translational significance across various fields. Due to the mostly preclinical characteristics of the evidence foundation, clinical application will necessitate authenticated biomarkers, standardized natural product formulations, pharmacokinetic and pharmacodynamic assessments, and regulated human studies.
逐年被引趋势
暂无年度引用数据
关键指标
同类平均 = 1
同领域 · 同年份 · 同类型
Google Scholar 与 OpenAlex 的被引统计范围不同,数值存在差异属正常。
AI 辅助阅读
依据:摘要
可就本文提问;依据不足时会说明。
学术脉络
学科主题
生物医学Gut microbiota and health
Tryptophan and brain disorders · Drug Transport and Resistance Mechanisms
参考文献 48
此处列出前 3 条